Skip Navigation


JAC Advance Access originally published online on September 29, 2004
Journal of Antimicrobial Chemotherapy 2004 54(5):915-920; doi:10.1093/jac/dkh428
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
54/5/915    most recent
dkh428v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Armbruster, C.
Right arrow Articles by Katinger, H. W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Armbruster, C.
Right arrow Articles by Katinger, H. W. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC vol.54 no.5 © The British Society for Antimicrobial Chemotherapy 2004; all rights reserved

Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12

Christine Armbruster1,*, Gabriela M. Stiegler2, Brigitta A. Vcelar3, Walter Jäger4, Ursula Köller5, Ruth Jilch5, Christoph G. Ammann6, Monika Pruenster6, Heribert Stoiber6 and Hermann W. D. Katinger2,3

1 2nd Medical Department/SMZ Baumgartner Höhe, Mantlergasse 23/2/12, A-1130 Vienna; 2 Institute of Applied Microbiology, Vienna; 3 Polymun Scientific Immunobiological Research GmbH, Vienna; 4 Institute of Pharmaceutical Chemistry, University of Vienna, Vienna; 5 Institute of Medical and Chemical Laboratory Diagnostics, KH Lainz, Vienna; 6 Institute of Hygiene and Social Medicine, University of Innsbruck, Innsbruck, Austria

* Corresponding author. Tel/Fax: +43-1-877-58-20; Email: christine.armbruster{at}gmx.at

Objectives: To study the safety, immunogenicity and pharmacokinetics of the human monoclonal antibody (hMAb) 4E10 alone and in combination with the hMAbs 2F5 and 2G12 in HIV-1-infected persons.

Materials and methods: Eight healthy volunteers with ≥350 CD4 cells/mm3 and ≤100 000 HIV-1 RNA copies/mL were enrolled, seven finished the study. A single 4E10 infusion was administered on day 0, followed by three doses of the hMAb combination 4E10/2F5/2G12 on days 7, 14 and 21 (total amount 8.5 g). Safety was assessed by physical examination, blood chemistry, complete blood cell count and recording of adverse events. 4E10, 2F5 and 2G12 plasma levels were determined before and at the end of each infusion and during the 7 week follow-up.

Results: No drug-related adverse events were observed throughout the study. The median plasma concentrations immediately after the first infusion were 371, 253 and 139 µg/mL for 4E10, 2F5 and 2G12. Multiple infusions resulted in maximum plasma concentrations of 407, 294 and 210 µg/mL for 4E10, 2F5, and 2G12, respectively. The median elimination half-lives (t1/2ß) were 6.6, 3.2 and 14.1 days for 4E10, 2F5 and 2G12. A low level antibody response against 2G12 was found in two patients.

Conclusion: This Phase I trial showed that the hMAb 4E10 can be safely administered, both alone and in combination with 2F5 and 2G12 to HIV-1-infected patients.

Keywords: human neutralizing monoclonal antibodies , pharmacokinetics , safety , HIV infection


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Virol.Home page
R. J. Luallen, J. Lin, H. Fu, K. K. Cai, C. Agrawal, I. Mboudjeka, F.-H. Lee, D. Montefiori, D. F. Smith, R. W. Doms, et al.
An Engineered Saccharomyces cerevisiae Strain Binds the Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody 2G12 and Elicits Mannose-Specific gp120-Binding Antibodies
J. Virol., July 1, 2008; 82(13): 6447 - 6457.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
A. Trkola, H. Kuster, P. Rusert, V. von Wyl, C. Leemann, R. Weber, G. Stiegler, H. Katinger, B. Joos, and H. F. Gunthard
In Vivo Efficacy of Human Immunodeficiency Virus Neutralizing Antibodies: Estimates for Protective Titers
J. Virol., February 1, 2008; 82(3): 1591 - 1599.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Mehandru, B. Vcelar, T. Wrin, G. Stiegler, B. Joos, H. Mohri, D. Boden, J. Galovich, K. Tenner-Racz, P. Racz, et al.
Adjunctive Passive Immunotherapy in Human Immunodeficiency Virus Type 1-Infected Individuals Treated with Antiviral Therapy during Acute and Early Infection
J. Virol., October 15, 2007; 81(20): 11016 - 11031.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
M. Sack, A. Paetz, R. Kunert, M. Bomble, F. Hesse, G. Stiegler, R. Fischer, H. Katinger, E. Stoeger, and T. Rademacher
Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures
FASEB J, June 1, 2007; 21(8): 1655 - 1664.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. van Montfort, A. A. Nabatov, T. B. H. Geijtenbeek, G. Pollakis, and W. A. Paxton
Efficient Capture of Antibody Neutralized HIV-1 by Cells Expressing DC-SIGN and Transfer to CD4+ T Lymphocytes
J. Immunol., March 1, 2007; 178(5): 3177 - 3185.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
B. Joos, A. Trkola, H. Kuster, L. Aceto, M. Fischer, G. Stiegler, C. Armbruster, B. Vcelar, H. Katinger, and H. F. Gunthard
Long-Term Multiple-Dose Pharmacokinetics of Human Monoclonal Antibodies (MAbs) against Human Immunodeficiency Virus Type 1 Envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5).
Antimicrob. Agents Chemother., May 1, 2006; 50(5): 1773 - 1779.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.